Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 504

Manolis Kellis, an accomplished Computer Science Professor at MIT and member of the Broad Institute, is a trailblazer in computational biology. Renowned for leading the MIT Computational Biology Group, his impactful research spans disease genetics, epigenomics, and gene circuitry. With numerous cited publications and leadership in transformative genomics projects, Kellis has garnered prestigious accolades, including the PECASE and Sloan Fellowship, shaping the field with his international perspective from Greece and France to the US.

Fuel your success with Forbes. Gain unlimited access to premium journalism, including breaking news, groundbreaking in-depth reported stories, daily digests and more. Plus, members get a front-row seat at members-only events with leading thinkers and doers, access to premium video that can help you get ahead, an ad-light experience, early access to select products including NFT drops and more:

https://account.forbes.com/membership/?utm_source=youtube&ut…ytdescript.

Stay Connected.
Forbes newsletters: https://newsletters.editorial.forbes.com.
Forbes on Facebook: http://fb.com/forbes.
Forbes Video on Twitter: http://www.twitter.com/forbes.
Forbes Video on Instagram: http://instagram.com/forbes.
More From Forbes: http://forbes.com.

Forbes covers the intersection of entrepreneurship, wealth, technology, business and lifestyle with a focus on people and success.

Read more | >

AN EXTRAORDINARY WAVE OF PROGRESS against cancer has occurred in the United States over the past three decades. From its peak in 1991, cancer mortality has declined by more than a third. Smoking cessation, human papillomavirus (HPV) vaccination, improved cancer screening and better cancer treatments are poised to push cancer deaths even lower. In 2022, this prompted President Joe Biden to reignite the Cancer Moonshot launched in 2016 with a goal of reducing cancer death rates even further—cutting them in half over the next 25 years.

With growing success in the treatment of many cancers has come a reexamination of the profound impact cancer treatment has on those with the disease. A cancer survivor faces a plethora of physical, emotional, social and financial challenges. Surgery, radiation therapy, chemotherapy and immunotherapy are all plagued by short-term toxicities and longer-term complications that can dominate life during and after cancer treatment and impinge upon its quality.

Fortunately, the same detailed knowledge of cancer genes and gene programs that has led to spectacular advances in cancer treatment may also improve cancer survivorship. Molecular profiling of individual cancers is now commonly used in cancer treatment planning. Breast cancer, long known to be a highly heterogeneous collection of diseases, provides a compelling example. For many years, testing breast tumor tissues for the presence of the estrogen receptor (ER), the progesterone receptor (PR) and the human epidermal growth factor receptor 2 (HER2) has been essential to steering women with breast cancer toward or away from endocrine therapies or agents like Herceptin (trastuzumab) that bind to HER2. Newer molecular profiling tools—including Oncotype DX, MammaPrint, Breast Cancer Index, EndoPredict and the Prosigna Breast Cancer Prognostic Gene Signature Assay—have further refined and individualized breast cancer treatment decision-making.

Read more | >

We don’t have a cure for Parkinson’s disease yet, but a recently discovered mutation in mitochondrial DNA that seems to protect the body against the condition could one day point the way to one. Discovered in a small protein called SHLP2, the genetic variant is relatively rare – found in just 1 percent of Europeans. Yet an analysis of the health records of 16,167 people led by researchers from the University of Southern California (USC) suggests…

Read more | >

The transcription factor FOXP3’s interactions with DNA present more evidence of the importance of disorder.

Since its earliest days, supramolecular chemistry has taken inspiration from biology. To create a ‘chemistry beyond the molecule’, supramolecular chemists can learn from the way nature builds hierarchies of organisation from the selective and orderly interactions of molecular components. At least, that’s what Jean-Marie Lehn and I argued in an overview of the subject in 2000.1 Yet while I still believe that today, I’m less sure that nature’s molecular principles can be easily translated into what Lehn has called a rational ‘science of informed matter’2 – and even less so that the principles used in supramolecular chemistry to create wonderful edifices of molecular order and design will by themselves give us anything like proto-living systems.

The reason is that life’s molecular principles are far less transparent than we thought even a few decades ago, and certainly less amenable to rational bottom-up design. An example is supplied by a new study of how a transcription-factor protein called FOXP3 interacts with DNA to influence the differentiation of regulatory T (Treg) cells, key components of the immune system, from their precursor cells. Transcription factors regulate gene expression, and one way FOXP3 seems to do this is by binding directly to DNA as dimers in which two of the proteins sit in ‘head-to-head’ contact.

Read more | >

“The bottom-line finding is that cannabis before exercise seems to increase positive mood and enjoyment during exercise, whether you use THC or CBD. But THC products specifically may make exercise feel more effortful,” said Dr. Laurel Gibson.

How does cannabis influence workouts? Does it serve as a performance enhancer or in other ways? This is what a recent study published in Sports Medicine hopes to address, as a team of researchers from the University of Colorado Boulder (CU Boulder) and the University of Colorado Anschutz Medical Campus investigated how cannabis influences exercise workouts and regimens, specifically pertaining to the exercise performance. This study comes almost a decade since Colorado legalized the sale of recreational marijuana and holds the potential to help researchers and the public better understand cannabis’ role in our everyday lives.

For the first-of-its-kind study that started in 2021, the researchers recruited 42 participants who were consistent cannabis users ages 21 to 39 to ascertain their responses to exercise after using cannabis and in a controlled laboratory setting. In the end, the participants reported increased enjoyment and “runner’s high” characteristics while also reporting greater levels of exertion during their exercise regimen. Additionally, the participants reported the following when the researchers asked them why they combine cannabis with their workout routines: 90.5 percent said it increases enjoyment, 69 percent said it reduces pain, 59.5 percent said it increases focus, 57.1 percent said it increases motivation, 45.2 percent stated they perceived that it speeds up time, and 28.6 percent said it improves their performance.

Read more | >

Fresh from announcing positive Phase 1 trial results for its inflammation-targeting drug candidate, Utah-based biotech Halia Therapeutics is now pursuing Phase 2 studies in a range of indications. The Salt Lake City company’s lead compound is an inhibitor of the NLRP3 inflammasome, a known driver of systemic chronic inflammation, which is linked to conditions including fibrotic disease, Alzheimer’s, Parkinson’s and many others.

Halia is taking a unique approach to the NLRP3 inflammasome by targeting the protein NEK7, which plays a key role in gene’s activity. In preclinical models, the company has shown its approach disrupts the formation of the NLRP3 inflammasome and promotes its disassembly once activated, reducing the overall inflammatory response. In its recent Phase 1 trial, in addition to showing positive safety and tolerability data, Halia’s drug demonstrated positive effects in blood samples taken from healthy volunteers, showing “over 90% suppression of multiple NLRP3-mediated cytokines and chemokines.”

Longevity. Technology: Chronic inflammation is a frequent topic of discussion in longevity circles. The term “inflammaging” refers to the increase of inflammatory cytokines in our bodies as we age, which is linked to chronic morbidity, disability, frailty and premature death. While there is no doubt that Halia believes that its approach can potentially impact many diseases, does the company have aging itself in its sights? We caught up with CEO Dr David Bearss to find out.

Read more | >

Have you heard of (MTC)? While ThyroidCancer is fairly common, there are four different types of thyroid cancers and MTC is the rarest type making up 3% of 4% of all thyroid cancers. Check out our expert reviewed summary for more.

Medullary thyroid cancer, or MTC, is a cancer that forms in the thyroid. The thyroid is a gland located in the front of your neck, just below the Adam’s apple. It is responsible for sending out hormones to the rest of your body. The inside of the thyroid is called the medulla. The medulla contains special cells called parafollicular C cells that produce and release hormones. MTC happens when the C cells become cancerous and grow out of control. MTC may also be called medullary thyroid carcinoma.

How common is medullary thyroid cancer?

Thyroid cancer is fairly common. There are four different types of thyroid cancers and MTC is the rarest type making up 3% to 4% of all thyroid cancers. About 1,000 people are diagnosed with MTC each year in the U.S.

Read more | >